Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares climbed 4.96% to $3.60. The company on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was 11.37% in last session and finished the day at $3.82. Traded volume was 14,321,730 million shares in the last session and the average volume of the stock remained 7.54 million shares. The beta of the stock remained 3.68. Inovio Pharmaceuticals Inc (NYSEMKT:INO)insider ownership is 0.30%.

Shares of polarizing clinical-stage immunotherapy developer Galena Biopharma (NASDAQ:GALE) also roared higher by 9.2% after research firm Maxim Group came to its defense, and noted that its fundamentals are sound despite its ongoing SEC investigation involving its relationship with a third-party according to Barron’s. Galena Biopharma Inc (NASDAQ:GALE) rose 9.22 percent to $3.08 yesterday on volume of 9.07 million shares. The intra-day range of the stock was $2.82 to $3.26. Galena Biopharma Inc (NASDAQ:GALE) has a market capitalization of $ 324.13 million.

CEL-SCI Corporation (NYSEMKT:CVM)’s stock which has grown by almost 130% since its low of $0.53 on Dec 19, 2013. The buzz in the market is that Cel-Sci could be on the cusp of announcing some sort of a major breakthrough in cancer treatment which will radically change the cancer treatment method in the years to com. CEL-SCI Corporation (NYSEMKT:CVM)’s stock on Mar19, 2014 reported a increase of 11.92% to the closing price of $1.69. Its fifty two weeks range is $0.53 -$3.09. The total market capitalization recorded $94.54 million. The overall volume in the last trading session was 7,544,050 million shares. In its share capital, CEL-SCI Corporation (NYSEMKT:CVM) has 48.22 million outstanding shares.

Synthetic Biologics Inc. (NYSEMKT:SYN) announced that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). On Wednesday, shares of Synthetic Biologics Inc (NYSEMKT:SYN) advanced 9.52% to close the day at $3.45. Company’s monthly performance is recorded as 30.19%. Synthetic Biologics Inc (NYSEMKT:SYN)quarterly revenue growth is 245.00%.